USFDA concludes inspection at Biocon Campus Site 1 facility of Biocon’s arm

01 Mar 2024 Evaluate

The U.S. Food and Drug Administration (USFDA) has concluded the inspection at Biocon’s subsidiary -- Biocon Biologics’ (BBL) Biocon Campus (Site 1) facility. USFDA had conducted an inspection at Biocon Biologics’ Biocon Campus (Site 1) facility between February 20-28, 2024.

At the conclusion of this inspection, the agency has issued Form 483s with 4 observations. The Company will submit a comprehensive Corrective and Preventive Action (CAPA) Plan to the U.S. FDA within the stipulated time and is committed to addressing these observations expeditiously. The outcome of this inspection at Site 1 does not impact the manufacturing and distribution of the Company’s commercial products in the US market.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

379.65 1.70 (0.45%)
09-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.95
Dr. Reddys Lab 1209.45
Cipla 1466.15
Zydus Lifesciences 894.95
Lupin 2181.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×